WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo ...
The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...
Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.
The CEO of Novo Nordisk is on Capitol Hill Tuesday to testify before a Senate committee about the high costs of its drugs ...
Sen. Bernie Sanders (I-Vt.) has once again criticized Novo Nordisk A/S (NYSE:NVO) for the high price of its diabetes drug, ...
Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback